Publications by authors named "U McGovern"
Article Synopsis
- The study investigates the effectiveness of the AKT inhibitor capivasertib when combined with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who did not respond well to prior treatments with abiraterone acetate and docetaxel.
- Conducted as a double-blind, randomized phase 2 trial with 100 men, the primary focus was on the composite response rate, which showed no significant improvement with the combination treatment compared to placebo.
- Analysis revealed that patients with PTEN loss had poorer overall survival regardless of treatment, with common side effects including diarrhea and fatigue, indicating that while the combination was tolerable, it did not enhance treatment outcomes.
Purpose: A DNA repair deficiency (DRD) phenotype exists within a subset of metastatic urothelial carcinomas (mUC) predicting benefit from platinum-based chemotherapy. We tested switch maintenance therapy with the poly ADP-ribose polymerase inhibitor rucaparib, following chemotherapy, for DRD biomarker-positive mUC.
Methods: DRD biomarker-positive mUC patients, within 10 weeks of chemotherapy, and without cancer progression, were randomly assigned (1:1) to maintenance rucaparib 600 mg twice a day orally, or placebo, until disease progression.
Article Synopsis
- The study investigates the genomic differences between primary prostate cancer and metastatic castration-resistant prostate cancer (mCRPC), analyzing biopsies from patients who developed mCRPC.
- Researchers examined 470 treatment-naive prostate cancer biopsies and 61 matched mCRPC biopsies, utilizing targeted and low-pass whole-genome sequencing to identify common mutations and copy number variations.
- Key findings include higher than previously reported mutations in TP53, BRCA2, and CDK12, and the discovery that RB1 loss in primary tumors correlates with poorer patient prognosis, indicating significant genomic differences between early-stage and more advanced cancer.